Sirolimus for Retinal Astrocytic Hamartoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04707209|
Recruitment Status : Recruiting
First Posted : January 13, 2021
Last Update Posted : January 13, 2021
|Condition or disease||Intervention/treatment||Phase|
|Retinal Astrocytic Hamartoma||Drug: Sirolimus||Not Applicable|
Retinal astrocytic hamartomas (RAH) are benign tumors of glial cells arising from astrocytes in the nerve-fiber layer of the retina. They are often associated with tuberous sclerosis complex (TSC) and, more rarely, neurofibromatosis type 1 (NF1). RAH may be caused by dysregulated tumor suppressors genes TSC1 or TSC2, which play a role in cell cycle regulation in retinal astrocytes via the PDGF-signalling pathway. Downregulation of TSC1 or TSC2 can result in hyperactivation of mTOR. Sirolimus is an inhibitor of mTOR, therefore inhibiting cell growth and proliferation of astrocytes. Systemic mTOR inhibitors (sirolimus and everolimus) have shown impressive reduction in the size of RAH in animal models and many human case series.
This single patient study is investigating the use of concurrent oral and intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes to improve intraocular response and reduce duration of treatment. The patient has no other clinical features suggestive of neurofibromatosis and a presumed diagnosis of tuberous sclerosis is being considered, with only two hypopigmented skin lesions noted.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intravitreal Injection of Sirolimus in the Treatment of Aggressive Retinal Astrocytic Hamartoma|
|Actual Study Start Date :||November 4, 2020|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||December 31, 2021|
|Experimental: Intravitreal Sirolimus||
An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.
Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.
Injections will be repeated every eight weeks. A total of 3-6 injections will be given per eye, over 6-12 months. The current treatment plan is for a maximum of six injections per eye, which may be amended to accommodate more in the future.
Other Name: DE-109
- Size of Retinal Astrocytic Hamartomas compared to baseline [ Time Frame: 14 months ]Measured by ophthalmic imaging
- Amount of retinal exudate compared to baseline [ Time Frame: 14 months ]Measured by ophthalmic imaging
- Retinal detachment progression/regression compared to baseline [ Time Frame: 14 months ]Measured by ophthalmic imaging
- Visual acuity compared to baseline [ Time Frame: 14 months ]Measured using logMAR virtual activity test
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04707209
|Contact: Ashwin Mallipatna, MD||416-813-7654 ext email@example.com|
|Contact: Kaitlyn Flegg, MSc||416-813-7654 ext firstname.lastname@example.org|
|The Hospital for Sick Children||Recruiting|
|Toronto, Ontario, Canada, M5G1X8|
|Contact: Kaitlyn Flegg, MSc 416-813-7654 ext 203287 Kaitlyn.email@example.com|